Immunoassays Compared for Diagnosis of Acute Murine Typhus Infections
|
By LabMedica International staff writers Posted on 10 Sep 2019 |

Image: A photomicrograph of an immunofluorescence assay (IFA) for Rickettsia (Photo courtesy of Fuller Laboratories).
Murine typhus is a disease transmitted by fleas and is caused by intracellular gram-negative bacteria called Rickettsia typhi, and manifested clinically with acute fever, chills, muscle pain, nausea, vomiting, stomach pain, cough and rash.
Appropriate rapid diagnostics are needed to distinguish it from other infections, as patient management varies. Due to low rickettsemia during acute illness, the sensitivity of real-time polymerase chain reaction (PCR) is highly variable. Thus, sero-diagnosis using immunofluorescence assay (IFA) remains the gold standard.
Scientists working with the Indonesia Research Partnership on Infectious Disease (Jakarta, Indonesia) obtained samples from eight government referral teaching hospitals in seven provincial capitals. Paired acute and convalescent plasma samples from 40 cases with confirmed R. typhi and 58 controls with another confirmed infection were used to evaluate the performance of commercial IgM and IgG enzyme-linked immunosorbent assay (ELISA) and IFA. The 58 paired plasma specimens that they used for controls were negative for R. typhi and Rickettsia spp., but positive for other pathogens by culture or molecular testing.
The immunofluorescence assay (IFA) was performed using kits from Focus Diagnostics (Cypress, CA, USA). The dilution for study samples was 1:64, and for provided positive controls was 1:32. Acute and convalescent specimens from each subject were performed simultaneously. Acute and convalescent plasma were tested simultaneously using ELISA kits from Fuller Laboratories (Fullerton, CA, USA). Microwells were coated with the outer surface membrane protein rOmp B purified from R. typhi. Optical density (OD) was measured at a wavelength of 450 nm.
The team reported that sensitivity and specificity of combined ELISA IgM and IgG anti-R. typhi using paired specimens were excellent (95.0% and 98.3%, respectively), comparable to combined IFA IgM and IgG (97.5% and 100%, respectively); sensitivity of ELISA IgM from acute specimens only was poor (45.0%), but specificity was excellent (98.3%). IFA IgM was more sensitive (77.5%), but less specific (89.7%) for single specimens. IgM was detected as early as day three of fever by ELISA and day four by IFA. Starting from day nine of illness, IgM was detected in all cases by IFA, while ELISA missed two specimens (days 10 and 25).
The authors concluded that their data supports the validity of ELISA in the diagnosis of R. typhi infection. As the specificity in acute specimens as well as sensitivity and specificity in convalescent specimens and paired specimens were excellent, ELISA is recommended when fluorescence microscopy is not feasible. However, IFA remains the method of choice if resources are available. ELISA is appropriate for resource-limited settings as it is easy to read, is objective, and has a high throughput. The study was published on August 26, 2019, in the journal Vector-Borne and Zoonotic Diseases.
Related Links:
Indonesia Research Partnership on Infectious Disease
Focus Diagnostics
Fuller Laboratories
Appropriate rapid diagnostics are needed to distinguish it from other infections, as patient management varies. Due to low rickettsemia during acute illness, the sensitivity of real-time polymerase chain reaction (PCR) is highly variable. Thus, sero-diagnosis using immunofluorescence assay (IFA) remains the gold standard.
Scientists working with the Indonesia Research Partnership on Infectious Disease (Jakarta, Indonesia) obtained samples from eight government referral teaching hospitals in seven provincial capitals. Paired acute and convalescent plasma samples from 40 cases with confirmed R. typhi and 58 controls with another confirmed infection were used to evaluate the performance of commercial IgM and IgG enzyme-linked immunosorbent assay (ELISA) and IFA. The 58 paired plasma specimens that they used for controls were negative for R. typhi and Rickettsia spp., but positive for other pathogens by culture or molecular testing.
The immunofluorescence assay (IFA) was performed using kits from Focus Diagnostics (Cypress, CA, USA). The dilution for study samples was 1:64, and for provided positive controls was 1:32. Acute and convalescent specimens from each subject were performed simultaneously. Acute and convalescent plasma were tested simultaneously using ELISA kits from Fuller Laboratories (Fullerton, CA, USA). Microwells were coated with the outer surface membrane protein rOmp B purified from R. typhi. Optical density (OD) was measured at a wavelength of 450 nm.
The team reported that sensitivity and specificity of combined ELISA IgM and IgG anti-R. typhi using paired specimens were excellent (95.0% and 98.3%, respectively), comparable to combined IFA IgM and IgG (97.5% and 100%, respectively); sensitivity of ELISA IgM from acute specimens only was poor (45.0%), but specificity was excellent (98.3%). IFA IgM was more sensitive (77.5%), but less specific (89.7%) for single specimens. IgM was detected as early as day three of fever by ELISA and day four by IFA. Starting from day nine of illness, IgM was detected in all cases by IFA, while ELISA missed two specimens (days 10 and 25).
The authors concluded that their data supports the validity of ELISA in the diagnosis of R. typhi infection. As the specificity in acute specimens as well as sensitivity and specificity in convalescent specimens and paired specimens were excellent, ELISA is recommended when fluorescence microscopy is not feasible. However, IFA remains the method of choice if resources are available. ELISA is appropriate for resource-limited settings as it is easy to read, is objective, and has a high throughput. The study was published on August 26, 2019, in the journal Vector-Borne and Zoonotic Diseases.
Related Links:
Indonesia Research Partnership on Infectious Disease
Focus Diagnostics
Fuller Laboratories
Latest Microbiology News
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
Channels
Clinical Chemistry
view channel
Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, triggering inflammation, pain, and scarring. Diagnosis often relies on surgery and, in the UK, takes an average of... Read more
Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for the Access p‑Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms... Read moreMolecular Diagnostics
view channel
Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. Genetic testing clarifies many drivers, yet it... Read more
Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more
Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
Lung cancer remains a leading cause of cancer death, and early-stage disease often produces few symptoms, complicating timely diagnosis and risk stratification. Conventional imaging and tissue biopsy have... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreMicrobiology
view channel
CE-Marked Blood Assay Automates Tuberculosis Infection Testing
Tuberculosis continues to pose a major global health challenge, with an estimated 10.7 million people falling ill and 1.23 million deaths in 2024. Roughly one quarter of the world’s population is believed... Read more
Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Genomic surveillance is essential for detecting viral variants before they spread widely, yet many public health systems face high costs, uneven capacity, and computational barriers. Existing analytic... Read more
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read morePathology
view channel
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
EBV Status Helps Predict Survival in Primary CNS Lymphoma
Primary central nervous system lymphoma is a rare malignancy in which tumors arise in the brain and, less often, the spinal cord, eyes, or cerebrospinal fluid. Outcomes are especially variable when the... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more




.jpg)



